MX2009003750A - Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. - Google Patents

Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.

Info

Publication number
MX2009003750A
MX2009003750A MX2009003750A MX2009003750A MX2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A
Authority
MX
Mexico
Prior art keywords
intraocular pressure
a3ar
antagonist
adenosine
species
Prior art date
Application number
MX2009003750A
Other languages
English (en)
Spanish (es)
Inventor
Marcel Y Avila
Richard Stone
Civan M Mortimer
Kenneth A Jacobson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2009003750A publication Critical patent/MX2009003750A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
MX2009003750A 2006-10-06 2007-10-05 Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. MX2009003750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85017506P 2006-10-06 2006-10-06
PCT/US2007/021409 WO2008045330A2 (en) 2006-10-06 2007-10-05 Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure

Publications (1)

Publication Number Publication Date
MX2009003750A true MX2009003750A (es) 2009-06-18

Family

ID=39283379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003750A MX2009003750A (es) 2006-10-06 2007-10-05 Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.

Country Status (8)

Country Link
US (1) US20090258836A1 (https=)
EP (1) EP2076267A4 (https=)
JP (1) JP2010505848A (https=)
AU (1) AU2007307157A1 (https=)
BR (1) BRPI0715318A2 (https=)
CA (1) CA2665616A1 (https=)
MX (1) MX2009003750A (https=)
WO (1) WO2008045330A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) * 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
HK1254892A1 (zh) 2016-01-14 2019-08-02 韩德株式会社 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
KR101805400B1 (ko) 2017-03-21 2017-12-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
KR102007640B1 (ko) * 2017-11-29 2019-08-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물
US11395597B2 (en) * 2018-06-26 2022-07-26 General Electric Company System and method for evaluating blood flow in a vessel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244774C (en) * 1996-01-29 2006-10-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dihydropyridine derivatives, their preparation and their use as adenosine receptor antagonists
ATE290910T1 (de) * 1998-07-16 2005-04-15 Univ Pennsylvania Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
AU2007307157A1 (en) 2008-04-17
EP2076267A4 (en) 2013-07-31
BRPI0715318A2 (pt) 2013-07-16
EP2076267A2 (en) 2009-07-08
CA2665616A1 (en) 2008-04-17
WO2008045330A3 (en) 2008-06-26
JP2010505848A (ja) 2010-02-25
WO2008045330A2 (en) 2008-04-17
US20090258836A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
MX2009003750A (es) Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
MY208749A (en) Biligand drug conjugates and uses thereof
EP2524693B1 (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP2533785B1 (en) Treatment of loss of sense of touch with saxitoxin derivatives
IL172082A0 (en) Foamable pharmaceutical compositions and methods for treating a disorder
EA024042B1 (ru) Способ снижения внутриглазного давления у людей
JP2010505848A5 (https=)
JP2017125074A (ja) 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
KR20060127843A (ko) 가령 황반 변성 치료제
WO2000012098A1 (en) Medicinal compositions for treating eye diseases
BR112018014467A2 (en) drug-antibody synergism technology for disease treatment
JP2014510782A5 (https=)
CN108261390A (zh) 一种布林佐胺溴莫尼定滴眼液及其制备方法
Bazotte et al. 4-Aminoquinoline compounds from the Spanish flu to COVID-19
NO20092764L (no) Isosorbid mononitrat derivater for behandling av okular hypertensjon
EP1754491A1 (en) Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
WO2012105610A1 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
JP2009519962A5 (https=)
EP1297849B1 (en) Remedial agent for optic nerve diseases
US20040192699A1 (en) Optic nerve protecting agents containing alpha1 receptor blocker as active ingredient
KR101891078B1 (ko) 황반변성 예방 또는 치료용 약학 조성물
CN108348516B (zh) 外用剂
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
CA2522318A1 (en) Drug for preventing or treating angiogenic eye diseases

Legal Events

Date Code Title Description
FG Grant or registration